Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Strohmaier, Susanne ^a   Edlinger, Michael ^a   Manjer, Jonas ^b   Stocks, Tanja ^c,d   Bjørge, Tone ^e,f   Borena, Wegene ^a   Häggström, Christel ^c   Engeland, Anders ^e,f   Nagel, Gabriele ^g,h   Almquist, Martin ^b   Selmer, Randi ^f   Tretli, Steinar ⁱ   Concin, Hans ^h   Hallmans, Göran ^c   Jonsson, Håkan ^c   Stattin, Pär ^c,j   Ulmer, Hanno ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d The Capital Region   (Denmark)

^e UNIVERSITY OF BERGEN   (Norway)

^f NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^g UNIVERSITY OF ULM   (Germany)

^h AGENCY FOR PREVENTIVE AND SOCIAL MEDICINE   (Austria)

ⁱ CANCER REGISTRY OF NORWAY   (Norway)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; CHOLESTEROL BLOOD LEVEL; FEMALE; FOLLOW UP; GALLBLADDER CANCER; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; LIVER CANCER; LYMPHATIC SYSTEM TUMOR; MAJOR CLINICAL STUDY; MALE; MELANOMA SKIN CANCER; METABOLIC SYNDROME X; NEOPLASM; NON MELANOMA SKIN CANCER; PANCREAS CANCER; SMOKING;

ADULT; AUSTRIA; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASMS; NORWAY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SMOKING; SWEDEN;

EID: 84872801071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054242     Document Type: Article

References (48)

1. Cambien F, Ducimetiere P, Richard J, (1980) Total serum cholesterol and cancer mortality in a middle-aged male population. Am J Epidemiol 112: 388-394.
2. Törnberg SA, Holm LE, Carstensen JM, Eklund GA, (1989) Cancer incidence and cancer mortality in relation to serum cholesterol. J Natl Cancer Inst 81: 1917-1921.
3. Williams RR, Sorlie PD, Feinleib M, McNamara PM, Kannel WB, et al. (1981) Cancer incidence by levels of cholesterol. JAMA 245: 247-252.
4. Stemmermann GN, Chyou PH, Kagan A, Nomura AM, Yano K, (1991) Serum cholesterol and mortality among Japanese-American men. The Honolulu (Hawaii) Heart Program. Arch Internal Med 151: 969-972.
5. Morris DL, Borhani NO, Fitzsimons E, Hardy RJ, Hawkins CM, et al. (1983) Serum cholesterol and cancer in the Hypertension Detection and Follow-up Program. Cancer 52: 1754-1759.
6. Kark JD, Smith AH, Hames CG, (1982) Serum retinol and the inverse relationship between serum cholesterol and cancer. BMJ (Clin Research Ed) 284: 152-154.
7. Schatzkin A, Hoover RN, Taylor PR, Ziegler RG, Carter CL, et al. (1987) Serum cholesterol and cancer in the NHANES I epidemiologic followup study. National Health and Nutrition Examination Survey. Lancet 2: 298-301.
8. Kagan A, McGee DL, Yano K, Rhoads GG, Nomura A, (1981) Serum cholesterol and mortality in a Japanese-American population: the Honolulu Heart program. Am J Epidemiol 1981114: 11-20.
9. Sherwin RW, Wentworth DN, Cutler JA, Hulley SB, Kuller LH, et al. (1987) Serum Cholesterol Levels and Cancer Mortality in 361662 Men Screened for the Multiple Risk Factor Intervention Trial. JAMA 257: 943-948.
10. Törnberg SA, Holm LE, Carstensen JM, Eklund GA, (1986) Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. N Engl J Med 315: 1629-1633.
11. Platz EA, Clinton SK, Giovannucci E, (2008) Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 123(7): 1693-1698.
12. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA, (2010) Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control 21: 61-68.
13. Mondul AM, Weinstein SJ, Virtamo J, Albanes D, (2011) Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control 22: 1545-1552.
14. Wingard DL, Criqui MH, Holdbook MJ, Barrett-Connor E, (1984) Plasma cholesterol and cancer morbidity and mortality in an adult community. J Chronic Dis 37: 401-406.
15. Hiatt RA, Fireman BH, (1986) Serum cholesterol and the incidence of cancer in a large cohort. J Chronic Dis 39: 861-870.
16. Yaari S, Goldbourt, Even-Zohar S, Neufeld HN, (1981) Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10 000 men. Lancet 1: 1011-1015.
17. Salonen JT, (1982) Risk of cancer and death in relation to serum cholesterol. A longitudinal study in an eastern Finnish population with high overall cholesterol level. Am J Epidemiol 116: 622-630.
18. Lim U, Gayles T, Katki HA, Stolzenberg-Solomon R, Weinstein SJ, et al. (2007) Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma. Cancer res 67: 5569-5574.
19. Andreotti G, Chen J, Gao Y-T, Rashid A, Chang S-C, et al. (2008) Serum lipid levels and the risk of biliary tract cancers and biliary stones: A population-based study in China. Int J Cancer 122: 2322-2329.
20. Schatzkin A, Hoover RN, Taylor PR, Ziegler RG, Carter CL, et al. (1988) Site-specific Analysis of Total Serum Cholesterol and Incident Cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer Res 48: 452-458.
21. Trompet S, Jukema JW, Katan MB, Blauw GJ, Sattar N, et al. (2009) Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol 170: 1415-1421.
22. Rose G, Shipley MJ, (1980) Plasma lipids and mortality: a source of error. Lancet 1: 523-526.
23. Isles CG, Hole DJ, Gillis CR, Hawthorne VM, Lever AF, (1989) Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey. BMJ (Clin Res Ed) 298: 920-924.
24. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, et al. (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 18: 2814-2821.
25. Strasak AM, Pfeiffer RM, Brant LJ, Rapp K, Hilbe W, et al. (2009) Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study. Ann Oncol 20: 1113-1120.
26. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, et al. (1999) Underestimation of Risk Associations Due to Regression Dilution in Long- term Follow-up of Prospective Studies. Am J Epidemiol: 341-353.
27. Whitlock G, Clark T, Vander Hoorn S, Rodgers A, Jackson R, et al. (2001) Random errors in the measurement of 10 cardiovascular risk factors. Eur J Epidemiol 17: 907-909.
28. Ulmer H, Kelleher C, Diem G, Concin H, (2003) Long-term tracking of cardiovascular risk factors among men and women in a large population-based health system: the Vorarlberg Health Monitoring & Promotion Programme. Eur Heart J 24: 1004-1013.
29. Clarke R, Lewington S, Youngman L, Sherliker P, Peto R, et al. (2002) Underestimation of the importance of blood pressure and cholesterol for coronary heart disease mortality in old age. Eur Heart J 23: 286-293.
30. Stocks T, Borena W, Strohmaier S, Bjørge T, Manjer J, et al. (2010) Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can). Int J Epidemiol 39: 660-667.
31. Wood AM, White I, Thompson SG, Lewington S, Danesh J, (2006) Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. I Int J Epidemiol 35: 1570-1578.
32. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 19 344(8934): 1383-1389.
33. Vitols S, Björkholm M, Gahrton G, Peterson C, (1985) Hypocholesterolaemia in malignancy due to elevetad low-density-lipoprotein-receptor activity in tomur cells: Evidence from studies in patients with leukemia. Lancet 326: 1150-1154.
34. Kritz H, Zielinski C, Sinzinger H, (1996) Low cholesterol and cancer. J Clin Oncol 14: 3043-3048.
35. Kitahara CM, Berrington de González A, Freedman ND, Huxley R, Mok Y, et al. (2011) Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 29: 1592-1598.
36. Kreger BE, Anderson KM, Schatzkin A, Splansky GL, (1992) Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study. Cancer 70: 1038-1043.
37. Law MR, Thompson SG, (1991) Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer causes & control 2: 253-261.
38. Borena W, Strohmaier S, Lukanova A, Bjørge T, Lindkvist B, et al. (2011) Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 131: 193-200.
39. Jiang J-T, Xu N, Zhang X-Y, Wu C-P, (2007) Lipids changes in liver cancer. Journal of Zhejiang University Science B 8: 398-409.
40. Batty GD, Kivimaki M, Morrison D, Huxley R, Smith GD, et al. (2009) Risk factors for pancreatic cancer mortality: extended follow-up of the original Whitehall Study. Cancer Epidemiol Biomarkers Prev 18: 673-675.
41. Berrington de Gonzalez A, Yun JE, Lee S-Y, Klein AP, Jee SH, (2008) Pancreatic cancer and factors associated with the insulin resistance syndrome in the Korean cancer prevention study. Cancer Epidemiol Biomarkers Prev 17: 359-364.
42. Johansen D, Stocks T, Jonsson H, Lindkvist B, Björge T, et al. (2010) Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev 19: 2307-2317.
43. Hiatt RA, Friedman GD, Bawol RD, Ury HK, (1982) Breast cancer and serum cholesterol. J Natl Cancer Inst 68: 885-889.
44. Törnberg SA, Holm LE, Carstensen JM, (1988) Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure. Acta oncologica (Stockholm, Sweden) 27: 31-37.
45. Bjørge T, Lukanova A, Jonsson H, Tretli S, Ulmer H, et al. (2010) Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 19: 1737-1745.
46. Fagherazzi G, Fabre A, Boutron-Ruault MC, Clavel-Chapelon F, (2010) Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. Eur J Cancer Prev 19: 120-125.
47. Dellavalle RP, Drake A, Graber M, Heilig LF, Hester EJ, et al. (2005) Statins and fibrates for preventing melanoma. Cochrane database of systematic reviews (Online): CD003697.
48. Jagtap D, Rosenberg CA, Martin LW, Pettinger M, Khandekar J, et al. (2012) Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative. Cancer. DOI:10.1002/cncr.27497.